Biotech & Pharma Updates | March 8 - 9, 2026
🧬 Novo Nordisk + Hims & Hers partner to sell GLP-1 drugs Ozempic and Wegovy, ending lawsuit dispute, Alfasigma + GSK strike $690M deal for linerixibat itching treatment awaiting FDA approval, Regeneron Pharmaceuticals reports positive Ph3 data for olatorepatide (olatorepatide) targeting GLP-1/GIP receptors for obesity treatment, Relmada Therapeutics raises $160M private placement, advancing oncology and CNS therapies, FDA's Prasad departure boosts rare disease biotechs uniQure, Replimune, Disc Medicine stock prices premarket Monday
